Kathryn Moore, PhD

Medicine (Cardiology) – Primary Mentor

Kathryn Moore is an Associate Professor at New York University School of Medicine in the Marc and Ruti Bell Vascular Biology and Disease Program. Dr. Moore is an established researcher in the field of inflammatory mechanisms of atherosclerosis, with research interests that include: (1) molecular mechanisms of sterile inflammation in atherosclerosis and Alzheimer’s disease, (2) regulation of cholesterol metabolism, and (3) role of positive and negative guidance cues in leukocyte trafficking. Using a variety of biochemical, genetic, cell and molecular biology techniques, Dr. Moore’s laboratory has uncovered novel roles for scavenger receptor, nuclear hormone receptor and Toll-like receptor pathways in the host response to infection and modified-self ligands that accumulate in disease states. Her research has improved our understanding of how immune cells respond to atherogenic lipids and b-amyloid, and contribute to the pathology that underlies sterile inflammatory diseases such as atherosclerosis and Alzheimer’s disease.  Dr. Moore’s research aims to further the understanding and prevention of chronic inflammatory disorders through interdisciplinary study of the molecular mechanisms regulating the initiation, promotion and resolution of macrophage inflammatory responses. This work has received extramural funding from the National Institutes of Health, Ellison Medical Foundation, American Heart Association and American Health Assistance Foundation.  Most recently, Dr. Moore was awarded a Challenge Grant from the NIH for her work on novel guidance cues regulating leukocyte trafficking and inflammation.  

Dr. Moore has been the recipient of numerous awards, including the Claflin Distinguished Scholar Award, the Ellison New Scholar in Aging Award and the American Heart Association’s Special Recognition Award in Vascular Biology. Dr. Moore serves on the editorial board of the Arteriosclerosis, Thrombosis and Vascular Biology journal and is a member of the American Heart Association’s Leadership Committee for Arteriosclerosis, Thrombosis and Vascular Biology, which provides input into the AHA’s science positions and recommendations for needed activities in the area of medicine and research in cardiovascular disease.